Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
| Revenue (Most Recent Fiscal Year) | $54.03M |
| Net Income (Most Recent Fiscal Year) | $-412.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 21.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -419.27% |
| Net Margin (Trailing 12 Months) | -418.24% |
| Return on Equity (Trailing 12 Months) | -35.67% |
| Return on Assets (Trailing 12 Months) | -33.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.24 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.69 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.70M |
| Free Float | 56.48M |
| Market Capitalization | $2.10B |
| Average Volume (Last 20 Days) | 1.24M |
| Beta (Past 60 Months) | 0.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |